Trial Profile
CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jan 2023
Price :
$35
*
At a glance
- Drugs Idecabtagene vicleucel (Primary) ; Dexamethasone; Lenalidomide; Nivolumab; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; First in man
- Sponsors Celgene Corporation
- 20 Jan 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results (n=4) evaluating nivolumab (anti-PD1)- based triplet therapy patients who were salvaged at the time of clinical relapse to first or second Idecabtagene Vicleucel infusion, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 20 Jan 2022 According to a Bristol-Myers Squibb media release, based on results from this and BB2121-MM-001 trials, the Japan's Ministry of Health, Labour and Welfare has approved Abecma (idecabtagene vicleucel), for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and have either experienced disease progression or relapse on the last therapy.